Addressing the challenge of rapid drug metabolite identification using Cyclic Ion Mobility Mass Spectrometry

Importance of the topic

The rapid and reliable identification of drug metabolites is essential in early drug discovery and ADME profiling to de-risk candidates, understand metabolic soft spots, and inform medicinal chemistry decisions. Conventional LC–MS workflows face a trade-off between throughput and chromatographic resolution: shortening LC gradients increases sample throughput but raises the risk of coelution, particularly for isobaric and positional isomers such as glucuronide conjugates. Combining high-speed UHPLC with cyclic ion mobility separation and orthogonal metrics (mass accuracy, fragmentation, collision cross section) addresses this bottleneck by improving separation, sensitivity, and confidence in metabolite annotation while maintaining fast turnaround.

Objectives and study overview

This study evaluated a rapid 10‑minute reversed‑phase UHPLC method coupled to cyclic ion mobility Q‑ToF MS (HDMSE, +ESI) to:

• Detect and annotate glucuronide metabolites formed in human hepatocyte incubations of diclofenac and raloxifene.
• Assess sensitivity gains using Wideband Enhancement (WBE).
• Demonstrate multipass ion mobility (extended ion flight path) to resolve isomeric glucuronides and enable shorter LC gradients.
• Integrate orthogonal ID metrics (accurate mass, fragments, predicted CCS) and workflow tools for high‑throughput processing.

Methodology

Drug incubations: Diclofenac and raloxifene were incubated separately at 1 µM with human hepatocytes at 1×10^6 cells/mL. Time‑course aliquots were taken from 0 to 60 minutes, quenched with methanol, vortexed, centrifuged and analyzed.

Chromatography and MS: A 10‑minute reversed‑phase UHPLC run was used prior to cyclic IMS–Q‑ToF acquisition in positive ESI using HDMSE (data‑independent acquisition). Ion mobility path length was varied (approx. 1–5 m effective path via multipass experiments) to probe resolution of isomeric species.

Data processing and ID criteria: Raw data were acquired in MassLynx and processed with waters_connect and MassMetaSite. Mass accuracy routinely achieved <2 ppm. Predicted CCS values from waters_connect CCS on Demand served as an orthogonal identification metric with acceptance criteria of ≤5% deviation. Fragmentation data and retention/drift times were used together for metabolite assignment.

Standards and calibration: Raloxifene glucuronide standards were used to assess linearity and sensitivity over 0.01–25 ng/mL. WBE (Wideband Enhancement) was evaluated by comparison of signal‑to‑noise and peak intensity with WBE enabled versus disabled.

Used instrumentation

• UHPLC system with 10‑minute reversed‑phase gradient.
• Cyclic ion mobility Q‑ToF mass spectrometer operating in HDMSE mode with positive ESI and adjustable multipass IMS (effective path lengths ~1–5 m).
• MassLynx data acquisition software.
• waters_connect (including CCS on Demand and reporting/visualization tools).
• MassMetaSite for metabolic prediction and structural annotation.

Main results and discussion

Metabolite detection: The workflow identified putative glucuronide metabolites of diclofenac and raloxifene with high mass accuracy (<2 ppm), supporting fragment ions and CCS metrics. For raloxifene, two glucuronide isomers were observed at 3.55 and 3.82 min in the 60‑minute timepoint.

Ion mobility separation: Extending the IMS flight path via multipass experiments improved separation of positional isomers. Raloxifene glucuronides with conjugation at the 4′ and 6′ positions were resolved in combined LC retention and drift time space when the IMS path length was increased, enabling discrimination of isomeric metabolites despite shortened LC gradients.

Sensitivity gains with WBE: WBE produced substantial sensitivity improvements. For diclofenac at 0.1 ng/mL, extracted chromatograms showed approximately a 10× higher response with WBE enabled. For raloxifene glucuronide standards, the lowest calibration point (0.01 ng/mL) yielded a peak‑to‑peak S/N of 24.5 with WBE versus 13.3 without, over a 0.01–25 ng/mL range (reported R2 values below 0.99 in this dataset). These gains improve limits of detection and quantification for low‑abundance metabolites.

Quantitative/time‑course capability: Time‑course plots produced in waters_connect tracked metabolite formation over the 0–60 min incubation period, demonstrating the workflow’s utility for kinetic profiling in hepatocyte assays.

Data interoperability: Processed outputs were compatible with third‑party tools (MassMetaSite), enabling automated transformation searches and annotation workflows that streamline metabolite identification.

Benefits and practical applications

• Improved confidence in metabolite annotation by combining accurate mass, fragment ions and predicted/experimental CCS as orthogonal identifiers.
• Higher sensitivity (up to ~10×) with WBE, lowering LOD/LOQ and enabling detection of trace metabolites.
• Faster sample throughput by using short UHPLC gradients while retaining the ability to resolve isomeric metabolites via multipass IMS.
• Seamless data processing and visualization in waters_connect and compatibility with MassMetaSite support streamlined HT ADME workflows.
• Applicable to early discovery ADME screening, metabolite identification campaigns, and quantitative metabolite monitoring.

Future trends and possibilities of use

Anticipated developments and opportunities include:

• Broader adoption of cyclic/multipass IMS in routine ADME labs to decouple chromatographic run time from isomer resolution.
• Expansion of CCS libraries and improvements in CCS prediction models to further strengthen orthogonal identification criteria.
• Integration with automated sample preparation and higher throughput LC (microflow/short gradients) for large screening campaigns.
• Application of machine learning to combine retention time, CCS, spectra and in‑silico predictions for automated, high‑confidence metabolite annotation.
• Standardization of WBE and IMS parameters across platforms to enable interlaboratory comparability and regulatory acceptance.

Conclusion

Combining rapid UHPLC with cyclic ion mobility Q‑ToF MS and Wideband Enhancement provides a practical solution to the throughput–resolution trade‑off in early ADME metabolite identification. Multipass IMS extends ion path length to separate isomeric glucuronides that coelute in short gradients, while WBE markedly improves sensitivity for low‑abundance species. The approach yields high‑confidence annotations by leveraging accurate mass, fragmentation and CCS metrics and integrates with vendor and third‑party software to support efficient workflows for discovery and lead optimization stages.

References

• Munjoma N, Marcotte A, Plumb R, Marsden‑Edwards E. Addressing the challenge of rapid drug metabolite identification using Cyclic Ion Mobility Mass Spectrometry. Waters Corporation poster, 2026.